Barings LLC grew its stake in Colgate-Palmolive (NYSE:CL) by 1,410.4% during the 4th quarter, HoldingsChannel.com reports. The firm owned 170,555 shares of the company’s stock after acquiring an additional 159,263 shares during the period. Barings LLC’s holdings in Colgate-Palmolive were worth $12,868,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors and hedge funds also recently modified their holdings of CL. Jacobi Capital Management LLC increased its position in Colgate-Palmolive by 125.5% during the third quarter. Jacobi Capital Management LLC now owns 1,443 shares of the company’s stock worth $104,000 after acquiring an additional 803 shares during the period. Krilogy Financial LLC grew its stake in Colgate-Palmolive by 23.0% during the second quarter. Krilogy Financial LLC now owns 1,547 shares of the company’s stock worth $115,000 after buying an additional 289 shares in the last quarter. Captrust Financial Advisors acquired a new stake in Colgate-Palmolive during the second quarter worth about $122,000. AlphaMark Advisors LLC grew its stake in Colgate-Palmolive by 1.5% during the second quarter. AlphaMark Advisors LLC now owns 1,698 shares of the company’s stock worth $126,000 after buying an additional 25 shares in the last quarter. Finally, Bruderman Asset Management LLC acquired a new stake in Colgate-Palmolive during the second quarter worth about $126,000. 71.52% of the stock is currently owned by institutional investors.
In other news, COO Noel R. Wallace sold 126,304 shares of the firm’s stock in a transaction that occurred on Wednesday, January 31st. The shares were sold at an average price of $73.78, for a total value of $9,318,709.12. Following the sale, the chief operating officer now directly owns 305,631 shares in the company, valued at approximately $22,549,455.18. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Vice Chairman Franck J. Moison sold 142,979 shares of the firm’s stock in a transaction that occurred on Tuesday, February 6th. The shares were sold at an average price of $70.09, for a total transaction of $10,021,398.11. Following the completion of the sale, the insider now owns 224,027 shares in the company, valued at $15,702,052.43. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 421,019 shares of company stock worth $30,031,097. 1.02% of the stock is currently owned by corporate insiders.
Shares of Colgate-Palmolive (NYSE:CL) opened at $70.03 on Wednesday. Colgate-Palmolive has a one year low of $68.19 and a one year high of $77.91. The company has a quick ratio of 1.00, a current ratio of 1.36 and a debt-to-equity ratio of 27.02. The firm has a market cap of $61,490.00, a P/E ratio of 27.04, a PEG ratio of 2.65 and a beta of 0.75.
Colgate-Palmolive (NYSE:CL) last posted its quarterly earnings results on Friday, January 26th. The company reported $0.75 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.75. Colgate-Palmolive had a net margin of 13.10% and a return on equity of 1,716.69%. The company had revenue of $3.89 billion for the quarter, compared to the consensus estimate of $3.92 billion. During the same period last year, the company posted $0.75 EPS. The firm’s quarterly revenue was up 4.6% compared to the same quarter last year. sell-side analysts anticipate that Colgate-Palmolive will post 3.18 earnings per share for the current year.
The business also recently declared a quarterly dividend, which was paid on Thursday, February 15th. Stockholders of record on Tuesday, January 23rd were paid a $0.40 dividend. The ex-dividend date was Monday, January 22nd. This represents a $1.60 dividend on an annualized basis and a dividend yield of 2.28%. Colgate-Palmolive’s payout ratio is currently 61.78%.
A number of equities research analysts have issued reports on the stock. Zacks Investment Research upgraded shares of Colgate-Palmolive from a “hold” rating to a “buy” rating and set a $84.00 price objective on the stock in a research note on Monday, January 8th. Macquarie upgraded shares of Colgate-Palmolive from a “neutral” rating to an “outperform” rating and set a $81.00 price objective on the stock in a research note on Tuesday, December 19th. BNP Paribas downgraded shares of Colgate-Palmolive from an “outperform” rating to an “underperform” rating in a research note on Tuesday, January 30th. Citigroup increased their price objective on shares of Colgate-Palmolive from $75.00 to $80.00 and gave the stock a “neutral” rating in a research note on Tuesday, January 30th. Finally, Deutsche Bank assumed coverage on shares of Colgate-Palmolive in a research note on Wednesday, December 13th. They set a “hold” rating and a $75.00 price objective on the stock. Three analysts have rated the stock with a sell rating, ten have issued a hold rating and five have assigned a buy rating to the stock. Colgate-Palmolive has a consensus rating of “Hold” and an average price target of $77.91.
WARNING: This piece of content was originally published by Stock Observer and is the sole property of of Stock Observer. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international copyright laws. The original version of this piece of content can be read at https://www.thestockobserver.com/2018/02/21/colgate-palmolive-cl-shares-bought-by-barings-llc.html.
Colgate-Palmolive Company (Colgate) is a consumer products company. The Company operates in two product segments: Oral, Personal and Home Care, and Pet Nutrition. The Oral, Personal and Home Care product segment is operated through five geographic segments, which include North America, Latin America, Europe, Asia Pacific and Africa/Eurasia.
Want to see what other hedge funds are holding CL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Colgate-Palmolive (NYSE:CL).
Receive News & Ratings for Colgate-Palmolive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Colgate-Palmolive and related companies with MarketBeat.com's FREE daily email newsletter.